AbstractObjective To analyze the prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery. Methods A retrospective analysis was performed among 74 patients with esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy and surgery from January 2007 to April 2014. All patients had preoperative stage cT3-4N0-1M0, consisting of 26 patients with stage cⅡ disease and 48 patients with stage cⅢ disease. Overall survival rates were estimated by the Kaplan-Meier method and compared using the Log-rank test for univariate analysis. Cox regression analysis was performed to provide multivariate analysis. Results The 1-, 3-, and 5-year overall survival (OS) rates were 85.7%, 50.0%, and 37.4% in patients with grade 1 tumor regression, 84.8%, 50.1%, and 46.3% in patients with grade 2 tumor regression, and 93.8%, 85.6%, and 85.6% in patients with grade 3 tumor regression, respectively (P=0.049). The 1-, 3-, and 5-year OS rates were 93.8%, 86.5%, and 86.5% in patients with pathologic complete response (pCR) and 85.2%, 52.4%, and 44.5% in patients without pCR, respectively (P=0.015). The 1-, 3-, and 5-year OS rates were 96.5%, 60.9%, and 57.1% in patients without pathologic lymph node metastasis (ypN-) and 57.1%, 35.7%, and 35.7% in patients with pathologic lymph node metastasis (ypN+), respectively (P=0.015). The 1-, 3-, and 5-year OS rates were 93.3%, 70.0%, and 62.1% in downstaged patients and 66.7%, 16.7%, and 16.7% in patients not downstaged, respectively (P=0.000). The multivariate analysis revealed that the ypN status and downstaging were independent prognostic factors for survival in patients (P=0.028;P=0.015). Conclusions Postoperative tumor regression grading is closely associated with prognosis. Particularly, patients with pCR have substantially improved survival. The ypN status and downstaging are independent prognostic factors for survival.
Corresponding Authors:
Wang Jianhua,Email:huanjianye@sina.cn
Cite this article:
Hao Daxuan,Yang Yuanyuan,Li Xue et al. Prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery [J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 447-451.
Hao Daxuan,Yang Yuanyuan,Li Xue et al. Prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery [J]. Chinese Journal of Radiation Oncology, 2016, 25(5): 447-451.
[1]赫捷,陈万青.2012中国肿瘤登记年报[M].北京:军事医学科学出版社, 2012:22-36. Hao J, Chen WQ.2012 Chinese cancer registry annual report[M].Beijing:Military Medical Science Press,2012:22-36. [2]平育敏,张毓德,杜喜群,等.食管癌和贲门癌20000例外科治疗经验[A]//中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集[C].郑州:河南省抗癌协会,2005:167-171. Ping YM,Zhang YD,Du XQ,et al. Experience in surgical treatment of 20000 cases of esophageal and cardiac carcinoma[A]//Proceedings of the first International Symposium on esophageal cancer in China and the Seventh National Symposium on esophageal cancer[C].Zhengzhou:Henan Cancer Society,2005:167-171. [3]邵令方,高宗人,许金良,等.食管癌和贲门癌的外科治疗15707例总结——附河南省食管癌的防治研究概况[A]//中国首届国际食管癌学术会议暨第七届全国食管癌学术会议论文集.郑州:河南省抗癌协会[C],2005:40-45. Shao LF,Gao ZR,Xu JL,et al. Surgical treatment of 15707 cases of esophageal cancer and cardiac cancer:a review of the research on the prevention and treatment of esophageal cancer in Henan Province[A]//Proceedings of the first International Symposium on esophageal cancer in China and the Seventh National Symposium on esophageal cancer[C].Zhengzhou:Henan Cancer Society,2005:40-45. [4]Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.DOI:10.1016/S1470-2045(11)70142-5. [5]van Hagen P,Hulshof MCCM,van Lanschot JJB,et al.preoperative chemoradiotherapy for esophageal or junction cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088. [6]Tepper J,Krasna MJ,Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26(7):1086-1092.DOI:10.1200/JCO.2007.12.9593. [7]Mariette C,Dahan L,Mornex F,et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer:final analysis of randomized controlled phase Ⅲ trial FFCD 9901[J].J Clin Oncol,2014,32(23):2416-2422.DOI:10.1200/JCO.2013.53.6532. [8]Kelsen DP,Winter KA,Gunderson LL,et al. Long-term results of RTOG trial 8911(USA Intergroup 113):a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer[J].J Clin Oncol,2007,25(24):3719-3725.DOI:10.1200/JCO.2006.10.4760. [9]Wu TT,Chirieac LR,Abraham SC,et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma:a reliable predictor for patient outcome[J].Am J Surg Pathol,2007,31(1):58-64.DOI:10.1097/01.pas.0000213312.36306.cc. [10]Burmeister BH,Smithers BM,Gebski V,et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomised controlled phase Ⅲ trial[J].Lancet Oncol,2005,6(9):659-668.DOI:10.1016/S1470-2045(05)70288-6. [11]杨弘,傅剑华,胡祎,等.术前放化疗并手术治疗局部晚期食管癌[J].中华医学杂志,2009,88(45):3182-3185.DOI:10.3321/j.issn:0376-2491.2008.45.003. Yang H,Fu JH,Hu Y,et al. Neo-adjuvant chemoradiotherapy followed by surgery in treatment of advanced esophageal carcinoma[J].Natl Med J China,2008,88(45):3182-3185.DOI:10.3321/j.issn:0376-2491.2008.45.003. [12]杨弘,傅剑华,刘孟忠,等.术前放化疗并手术治疗局部晚期食管鳞癌的多中心随机对照临床研究[J].中华医学杂志,2012,92(15):1028-1032.DOI:10.3760/cma.j.issn.0376-2491.2012.15.005. Yang H,Fu JH,Liu MZ,et al. A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus:an interim analysis[J].Natl Med J China,2012,92(15):1028-1032.DOI:10.3760/cma.j.issn.0376-2491.2012.15.005. [13]吴小源,邢文群,刘劲松,等.局部进展期食管鳞癌术前同期放化疗的Ⅱ期临床研究[J].中华放射肿瘤学杂志,2015,24(1):25-28.DOI:10.3760/cma.j.issn.1004-4221.2015.01.007. Wu XY,Xing WQ,Liu JS,et al. Stage Ⅱ clinical study of preoperative concurrent chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma[J].Chin J Radiat Oncol,2015,24(1):25-28.DOI:10.3760/cma.j.issn.1004-4221.2015.01.007. [14]Dittrick GW,Weber JM,Shridhar R,et al. Pathologic Nonresponders after Neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy[J].Ann Surg Oncol,2012,19(5):1678-1684.DOI:10.1245/s10434-011-2078-4. [15]Mandard AM,Dalibard F,Mandard JC,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations[J].Cancer,1994,73(11):2680-2686.DOI:10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C. [16]Chirieac LR,Swisher SG,Ajani JA,et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation[J].Cancer,2005,103(7):1347-1355.DOI:10.1002/cncr.20916. [17]Tong DK,Law S,Kwong DL,et al. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor[J].Ann Surg Oncol,2010,17(8):2184-2192.DOI:10.1245/s10434-010-0995-2. [18]Donahue JM,Nichols FC,Li Z,et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival[J].Ann Thorac Surg,2009,87(2):392-398.DOI:10.1016/j.athoracsur.2008.11.001. [19]Berger AC,Farma J,Scott WJ,et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival[J].J Clin Oncol,2005,23(19):4330-4337.DOI:10.1200/JCO.2005.05.017. [20]Guo K,Cai L,Zhang Y,et al. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy[J].Chin J Cancer,2012,31(8):399-408.DOI:10.5732/cjc.011.10406. [21]Robb WB,Dahan L,Mornex F,et al. Impact of Neoadjuvant Chemoradiation on Lymph Node Status in Esophageal Cancer:post hoc Analysis of a Randomized Controlled Trial[J].Ann Surg,2015,261(5):902-908.DOI:10.1097/SLA.0000000000000991. [22]Gu Y,Swisher SG,Ajani JA,et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation[J].Cancer,2006,106(5):1017-1025.DOI:10.1002/cncr.21693. [23]Hlscher AH,Drebber U,Schmidt H,et al. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma[J].Ann Surg,2014,260(5):779-785.DOI:10.1097/SLA.0000000000000964. [24]van Hagen P,Wijnhoven BP,Nafteux P,et al. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer[J].Br J Surg,2013,100(2):267-273.DOI:10.1002/bjs.8968.
2016, Vol. 25 
